The Effect of Ribavirin on Bone Density in Patients with Chronic Hepatitis C Treated with Interferon-Ribavirin Therapy

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Pediatric Gastroenterology and Nutrition - JPGN

• Publication date

  2005-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.mpg.0000182800.07794.01PMID 16254525
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ribavirin, but Not Interferon α-2b, is Associated with Impaired Osteoblast Proliferation and Differentiation In Vitro

  2004cited by this paper
• Vertebral osteopenia due to bone marrow hyperplasia during interferon-alpha and ribavirin therapy for chronic hepatitis C.

  2003cited by this paper
• Children with hepatitis C

  2002cited by this paper
• Lack of evidence for ribavirin‐induced bone loss

  2002cited by this paper
• Hepatitis C in childhood

  2002cited by this paper
• Calcium‐parathyroid hormone‐vitamin D axis and metabolic bone disease in chronic viral liver disease

  2001cited by this paper
• Comparative Effects of Different Doses of Ribavirin Plus Interferon-α2b for Therapy of Chronic Hepatitis C: Results of a Controlled, Randomized Trial

  2001cited by this paper
• Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.

  2000cited by this paper
• Impact of interferon alfa‐2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C

  2000cited by this paper
• Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C.

  2000influential reference
• Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

  1998cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

  1998cited by this paper
• Hepatitis C in childhood

  1995influential reference

• Pegylated interferon α/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection

  2017cites this paper
• Bone-Specific Alkaline Phosphatase Flare in a Patient with Hepatitis C: Case Report and Review of Literature

  2017cites this paper
• Bone Mineral Density Measurements, Bone Markers and Serum Vitamin D Concentrations in Men with Chronic Non-Cirrhotic Untreated Hepatitis C

  2013cites this paper
• Evaluation of the role of the antioxidant silymarin in modulating the in vivo genotoxicity of the antiviral drug ribavirin in mice.

  2013cites this paper
• Bone alterations in hepatitis C virus infected patients.

  2013cites this paper
• The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice

  2011cites this paper
• Classical and Emerging Roles of Vitamin D in Hepatitis C Virus Infection

  2011cites this paper
• Hepatitis C en población pediátrica: panorama actual Hepatitis C in children: Present overview

  2009cites this paper
• Interferon-induced Parkinsonism in a patient with chronic hepatitis C.

  2009cites this paper
• Evaluation of Ribavirin Genotoxicity with Sister Chromatid Exchange and Micronuclei Assays in Humans

  2009cites this paper
• Hepatitis C en población pediátrica: panorama actual

  2009cites this paper
• Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon α and ribavirin therapy

  2008cites this paper
• Ribavirin in the treatment of chronic hepatitis C

  2008cites this paper
• Treatment of viral hepatitis in children.

  2007cites this paper